Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX: PBT). Note: The request metadata references "Alterity Therapeutics Ltd," but the filing text explicitly identifies the registrant as Prana Biotechnology Limited.
Filing Type: Form 6-K (Report of Foreign Private Issuer).
Reporting Period: March 2014 (specifically March 11–17, 2014 for the issuance of securities).
Business Activity: The company is engaged in clinical development and research programs. The filing announces a new issue of ordinary shares to fund these activities and working capital.
Key Financial Metrics and Capital Structure
Capital Raised:
- Placement: AUD$5,447,894 raised from the issuance of 4,896,860 ordinary shares.
- Staff Options Exercise: AUD$262,894 raised from the exercise of 1,472,628 unlisted staff options.
- Total Consideration: AUD$5,710,788.
Share Capital:
- Ordinary Shares on Issue (Post-Issue): 429,475,350.
- Unlisted Options Outstanding: 18,171,724 options across various tranches with exercise prices ranging from $Nil to AUD$1.12 and expiry dates between 2014 and 2019.
Financial Performance: The filing text does not provide revenue, profit, cash flow, margins, or debt figures. This document is a capital issuance announcement, not a financial results report.
Material Changes
Capital Increase: The company increased its issued share capital by 6,369,488 ordinary shares (4,896,860 via placement and 1,472,628 via option exercises).
Regulatory Compliance: The company utilized its placement capacity under ASX Listing Rules 7.1 and 7.1A. The filing includes a "Cleansing Statement" under Section 708A(5) of the Corporations Act, confirming that the shares were issued without disclosure to investors under Part 6D.2 and that the company has complied with relevant continuous disclosure obligations.
Guidance, Outlook, and Risks
Purpose of Funds: Proceeds from the placement are designated to fund the company's current clinical development, research programs, and working capital as part of an on-going placement.
Management Commentary: The filing confirms that the new securities rank equally (pari passu) with existing ordinary shares from the date of allotment. The dividend policy remains unchanged.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond standard regulatory warranties regarding the legality of the issue and the absence of "excluded information" required to be disclosed.
Investor Verification Checklist
- Verify the total number of ordinary shares on issue (429,475,350) against the company's latest ASX announcements.
- Confirm the utilization of the company's 15% placement capacity (Rule 7.1) and 10% additional capacity (Rule 7.1A) as calculated in Annexure 1.
- Review the specific terms of the 18,171,724 unlisted options, particularly those expiring in 2014 (e.g., PBTAB expiring 7 Aug 2014).
- Check for subsequent filings regarding the progress of the clinical development programs funded by this capital raise.